Abstract
The Severe Acute Respiratory Syndrome COVID-19 virus (SARS-CoV-2) has had enormous impacts, indicating need for non-pharmaceutical interventions (NPIs) using Artificial Intelligence (AI) modeling. Investigation of AI models and statistical models provides important insights within the province of Ontario as a case study application using patients’ physiological conditions, symptoms, and demographic information from datasets from Public Health Ontario (PHO) and the Public Health Agency of Canada (PHAC). The findings using XGBoost provide an accuracy of 0.9056 for PHO, and 0.935 for the PHAC datasets. Age is demonstrated to be the most important variable with the next two variables being Hospitalization and Occupation. Further, AI models demonstrate identify the importance of improved medical practice which evolved over the six months in treating COVID-19 virus during the pandemic, and that age is absolutely now the key factor, with much lower importance of other variables that were important to mortality near the beginning of the pandemic.
An XGBoost model is shown to be fairly accurate when the training dataset surpasses 1000 cases, indicating that AI has definite potential to be a useful tool in the fight against COVID-19 even when caseload numbers needed for effective utilization of AI model are not large.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Research funding by both the Natural Sciences Engineering Research Council (NSERC) under their special program for analyses of COVID-19 (ALLRP 549866-20) and by the University of Guelph Research Leadership Chair program are gratefully acknowledged.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB / ethic approval was required
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos